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Introduction: Royal jelly is a substance that appears to be effective on immune system and it appears 
to be effective on both prevention and growth of cancer cells. In this study, we aimed to carry out a 
research to investigate the effect of royal jelly on the growth of WEHI-164 fibrosarcoma cell in syngenic 
Balb/c mice.
Methods: In an experimental study, 28 male Balb/c mice were designated into four equal groups. The 
mice were subcutaneously injected with 5x105 WEHI-164 tumor cells on the day zero in the chest area 
of the animal. Animals in groups 1 to 4 were orally given 100, 200, 300 mg/kg of royal jelly or vehicle, 
respectively. In every individual mouse, the tumour size was measured every 2 days from day 5 (days 
5, 7, 9, 11, 13, 15 and 17). Data were statistically analyzed using Kruskal-Wallis and Mann Whitney-U 
tests.
Result: Our results showed that the mean size of tumor in case group was significantly smaller than 
the control group in days 11, 13, 15 and 17 (P<0.05). No metastasis was seen in test and control groups.
Conclusion: With emphasize on antitumor effect of royal jelly, it seems that royal jelly has important 
role in control and regression of fibrosarcoma cells. Since royal jelly showed a delayed effect in control 
of fibrosarcoma, we suggest that royal jelly be used at least 10 days before tumor inoculation 
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Introduction
Fibrosarcoma is a tumor of mesenchymal cell origin that is 
composed of malignant fibroblasts in a collagen background. 
This tumor often involves muscle fascia deeply. The tumor 
may be infinitely large when it is diagnosed. The tumor usually 
appears in people younger than 20 years (1).
One of the known treatments for fibrosarcoma is 
radiotherapy, which prevents the rapid growth of cancer cells 
and causes the death of cancer cells (2,3). All the methods 
of treatment, including surgery, amputation, radiotherapy 
and chemotherapy have side effects such as hair loss, nausea, 
vomiting, skin rash and an increased risk of infection in 
result of  weakening immune system, while biological 
methods are non-invasive and effective (4). Enhancing of the 
immune system (immunotherapy) is one of the surveyed and 
effective treatments of the cancer. This method is focused on 
strengthening the immune system and stimulating factors of 
this system. Strengthening the immune system prevents or 
reduces cancer cells growth. Meanwhile, one of the materials 
which seems to be effective in enhancing the immune system 
is royal jelly (5,6). Royal jelly is one of the Bee products which 
is a milky white substance with a sharp smell and fruity taste 
and is nutritionally abundant. This gel contains all water-
soluble B vitamins such as thiamine (B1), riboflavin (B2), and 
pyridoxine (B6) as well as niacin, biotin, folic acid, inositol, 
and minerals (including sodium, potassium, chromium, 
magnesium, nickel) and 20 essential amino acids, sugars, 
sterols, phosphorus compounds, acetylcholine, gamma 
globulin, nucleic acids and nutrients needed for health (7,8).
 Royal jelly has a strong antibiotic activity against bacteria and 
fungi (9-12). Royal jelly effects on atherosclerosis, arthritis, 
diabetic foot ulcers, tissue repair, collagen, warts and estrogen-
like effects have also been demonstrated (13-18).
Regarding the anti-tumor effect of royal jelly, a group of 
Japanese researchers gave royal jelly to one of two groups 
of laboratory mice, prior to tumor cell implantation and 
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observed that the gel had no effect on leukemia cells but it had 
effects on sarcoma cells and increased the lifespan of mice by 
about 20%. In this study, the size of tumors decreased about 
50% (19). Other studies also have pointed to royal jelly’s anti-
tumor effects (21,22). In a study by Tamura et al, they found 
no antitumor effect for royal jelly, but it increased the lifespan 
of mice by as much as 19.3% and restricted tumor growth 
greatly (22). In a study conducted by Bincoletto et al, it was 
shown that royal jelly modulates the immune system and is 
effective anti-tumor response with a long treatment regimen 
(23). 
Fibrosarcoma is a soft tissue tumor with no pain which 
growths deeply and therefore its diagnosis happens later. On 
the other hand, at the diagnosis time it is such a big tumor 
that can involve muscle fascia and its boundaries are not clear, 
but early detection and treatment can increase the survival 
rate of patients. Since current treatments are not effective in 
the treatment of fibrosarcoma singly and the need for new 
treatments or a combination therapy are crucial, according to 
the antitumor and anti metastatic effects of royal jelly in many 
studies, It seems that this material is also effective against 
fibrosarcoma. Thus, this study aimed to determine the effects 
of royal jelly on WEHI-164 fibrosarcoma, in male mice Balb/c.
Material and Methods
In this study, 4 groups of 7 male Balb/c mice from similar age 
which obtained by the Pasteur Institute of Iran were selected. 
The mice were injected 5x105 164-WEHI tumor cells under 
the skin in the chest region. Each group except the control 
group received royal jelly orally at doses of 100, 200 and 300 
mg/kg at the beginning and through the study, after tumor 
cells inoculation (20). Bee royal jelly was obtained from the 
Agricultural Research Center of Chaharmahal and Bakhtiari. 
In order to measure the growth of malignant cells from the 
second day after the injection, each mouse was examined 
for the tumor mass by touching the injection site. When the 
tumor was touched by finger skin, its diameter was measured 
by caliper in two directions immediately. The study of the 
rats regarding the existence of the tumor and its diameter 
continued till two weeks after the injection. At this period, the 
tumor diameter was measured seven times and at the days 5, 
7, 9, 11, 13, 15 and 17 after the injection of tumor cells. In 
order to calculate the average tumor area, two perpendicular 
diameters were measured, added together and the sum was 
divided by the number 4. The result of the division was 
squared and was multiplied by 3.14, eventually (24). In order 
to compare the mean of the tumor areas in treated and control 
groups, Mann-Whitney and Kruskal-Wallis tests were used.
Results
The results of the growth of WEHI-164 tumor cells in Balb/c 
mice showed that no tumor growth was observed in the first, 
second and third days after tumor inoculation. The tumor 
was palpable on day fourth the fifth.  On the day seven tumor 
masses were observed in all animals. 
The results of measuring the size of tumor after the fifth day 
and for 7 consecutive times and every other day showed that 
the mean tumor area of control group (the group which did 
not receive the royal jelly) on days 11, 13, 15 and 17 were 
significantly higher than those of other three groups (the 
groups receiving 100, 200 and 300 mg/kg royal jelly) (P<0.05; 
Figure 1).
In order to show the metastasis of tumor in the lungs and 
livers of the animals, the organ cells were culture in tissue 
culture medium. No tumor cells growth were detected. In this 
study, all animals survived until the end of the study, and even 
after that.
Discussion
In this study, the effects of royal jelly on the growth and 
metastasis of malignant fibrosarcoma cells in Balb/c mice were 
studied. The results showed that the average size of tumors in 
mice receiving royal jelly was smaller than the control group. 
No Similar study is conducted to survey the effects of royal 
jelly on WEHI-164 fibrosarcoma in Balb/c mice, but the effect 
of royal jelly on other types of cancer in animal models was 
investigated. In a study conducted by a group of Japanese 
researchers the effects of royal jelly on cancer was investigated. 
In this study one of two groups of laboratory rats received 
royal jelly prior to tumor cell inoculation. The study shows that 
royal jelly has no effect on leukemia cells but has therapeutic 
effects on sarcoma cells (19). The results obtained in this study 
also show that the size of tumors in the control group is larger 
than their size in treated groups. It seems that during the study 
soft tissue cells have had no metastatic properties, because the 
metastasis in soft tissue fibrosarcoma is serotinal (21) or it 
occurs in longer periods of time. Therefore, In this study the 
anti-metastatic effect of royal jelly has been observed. 
In a study conducted by Tamvra and et al, royal jelly did not 
show any antitumor effects, but the lifetime has increased 3.19 
percent and the use of prophylaxis-therapy inhibits tumor 
growth, 1.49-1.56% (22). These findings also confirm the 
findings of the present study. 
Other study conducted by Bincoletto et al showed that 
royal jelly modulates body immune response and long-term 
treatment regimen resulted in anti-tumor effects. In this study, 
the prescribed royal jelly for 33 days at doses of 500, 1000 and 
1500 mg/kg increased the survival respectively 38, 85 and 71% 
Figure 1. The comparison of different concentrations of royal jelly on 
the growth of WEHI-164 fibrosarcoma tumor in Balb/c mice.
100, 200 and 300 mg/kg of royal jelly reduced the tumor size 
significantly at days 11, 13, 15 and 17 compare to control group 
(P<0.05).
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in the same dose for 23 and 28 days. The same dose for 23 and 
28 days increased survival rates by 19 and 23%. The increased 
survival rate may be due to the Prostaglandin E2 after the 
treatment. The results of the study changed royal jelly effects 
from a biological response to an anti-tumor agent (23).  In the 
study, all the rats survived until the end of the study, and even 
after that. The tumor used in this study is possibly according 
to the clashes of soft tissue and not observing metastasis have 
been ineffective on the survival of the rats. 
Considering that the early use of royal jelly had no effect on 
tumor growth, it seems that the effect of royal jelly on the 
immune system and its anti-tumor activity takes time and 
because of the small size of tumors in the early days, it’s not 
possible to comment about the effect of this material on tumor 
growth, but during the time and due to the effects of royal 
jelly on immune system, tumor growth decreases in compare 
to control group. Therefore it is suggested to begin treatment 
regimen of royal jelly sometimes before tumor injection in 
the future studies in order to make it ready to progress and 
prevent tumor growth. 
Also it is recommended to study the anti fibrosarcoma effects 
of royal jelly in the future researches in other laboratory 
animals, with different injection method. 
Conclusion
The results of the study show that 100, 200 and 300 kg/mg 
doses of royal jelly are effective on WEHI164 fibrosarcoma in 
Balb/c mice. This effect introduces the possible therapeutic 
and dietary use of royal jelly. 
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